Trial · NCT01444300

Dalfampridine for Imbalance in Multiple Sclerosis

NCT01444300, Phase 2, Completed, Oregon Health and Science University; results first posted 2014-06-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dalfampridine for Imbalance in Multiple Sclerosis. Trials, record NCT01444300. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01444300

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dalfampridine for Imbalance in Multiple Sclerosis
NCT number: NCT01444300
Status: Completed
Phases: Phase 2
Enrollment: 24 participants, actual
Lead sponsor: Oregon Health and Science University
Conditions: Multiple Sclerosis, Fatigue
Interventions: Dalfampridine, Placebo
First posted: 2011-09-30
Last updated: 2014-06-16
Results first posted: 2014-06-16

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Automatic Postural Response (APR )Latency	Baseline to 12 weeks	Automatic Postural Response (APR) latencies will be measured by Computerized Dynamic Posturography (CDP). The restoration of balance after an unexpected movement by Computerized Dynamic Posturography relies on automated postural responses in the upper and lower legs, trunk, shoulders, and neck muscles. APR latency is the reaction- time response to movements of the support surface on which the subject stands. These responses typically occur at onset latencies of \~100 milliseconds. In response to a change, both feet-in-place and stepping strategies can be used to recover balance, with the incidence of stepping responses becoming larger as the change magnitude increases voluntary movements in human subjects.
Secondary	Change in Activities-specific Balance Confidence (ABC) Questionnaire Scores	Baseline to 12 weeks	The ABC is an 11-point scale and subjects are asked to indicate personal level of confidence in doing specific activities without losing balance or becoming unsteady on a scale from 0% to 100%. The ratings are added (possible range =0 -1600) and divide by 16 to get each subject's ABC score. A high ABC score indicates a high degree of confidence and a low ABC score indicates a low degree of confidence.
Secondary	Change in Timed 25 Foot Walking Speed	Baseline to 12 weeks

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Automatic Postural Response (APR )Latency	Baseline to 12 weeks	milliseconds	MEAN
SECONDARY	Change in Activities-specific Balance Confidence (ABC) Questionnaire Scores	Baseline to 12 weeks	Scores on a scale	MEAN
SECONDARY	Change in Timed 25 Foot Walking Speed	Baseline to 12 weeks	seconds	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Automatic Postural Response (APR )Latency	Dalfampridine	5.71	Standard Deviation 16.2	milliseconds
Change in Automatic Postural Response (APR )Latency	Placebo	4.58	Standard Deviation 23.0	milliseconds
Change in Activities-specific Balance Confidence (ABC) Questionnaire Scores	Dalfampridine	1.30	Standard Deviation 9.02	Scores on a scale
Change in Activities-specific Balance Confidence (ABC) Questionnaire Scores	Placebo	0.41	Standard Deviation 10.7	Scores on a scale
Change in Timed 25 Foot Walking Speed	Dalfampridine	0.26	Standard Deviation 0.78	seconds
Change in Timed 25 Foot Walking Speed	Placebo	0.39	Standard Deviation 1.45	seconds

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Dalfampridine	12
Overall Study	STARTED	Placebo	12
Overall Study	COMPLETED	Dalfampridine	8
Overall Study	COMPLETED	Placebo	12
Overall Study	NOT COMPLETED	Dalfampridine	4
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Insomnia	Nervous system disorders	Dalfampridine	4	12	4
other	Insomnia	Nervous system disorders	Placebo	0	12	0
other	Nausea	Gastrointestinal disorders	Dalfampridine	5	12	5
other	Nausea	Gastrointestinal disorders	Placebo	0	12	0
other	Muscle weakness	Musculoskeletal and connective tissue disorders	Dalfampridine	2	12	2
other	Muscle weakness	Musculoskeletal and connective tissue disorders	Placebo	6	12	6
other	Balance problems	Musculoskeletal and connective tissue disorders	Dalfampridine	2	12	2
other	Balance problems	Musculoskeletal and connective tissue disorders	Placebo	4	12	4
other	Dizziness	Nervous system disorders	Dalfampridine	3	12	3
other	Dizziness	Nervous system disorders	Placebo	0	12	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dalfampridine
Total, all-cause mortality	Placebo
Total, other adverse events	Dalfampridine	9	12
Total, other adverse events	Placebo	10	12
Total, serious adverse events	Dalfampridine	0	12
Total, serious adverse events	Placebo	0	12

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Dalfampridine vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01444300

GET https://conductscience.org/api/trials/v1/NCT01444300/registered

API reference For AI assistants